Anti-Human Tissue Factor (TF) (Tisotumab) (HEK Expressed) – Fc Muted™

Research-grade Tisotumab biosimilars are used as calibration standards or reference controls in PK bridging ELISA to ensure precise, accurate, and comparable quantification of drug concentrations in serum samples across biosimilar and reference products.

In a typical PK bridging ELISA for biosimilars:

• Calibration Standards: Research-grade Tisotumab biosimilars are prepared at known concentrations and used to generate a standard curve. This curve establishes the relationship between ELISA signal (often optical density) and drug concentration, enabling quantification of unknown serum samples.
• Reference Controls: Both biosimilar and reference (innovator) Tisotumab products are assessed during method development to confirm that the assay quantifies them equivalently—this is crucial for demonstrating analytical comparability and PK bioequivalence.
• Single Analytical Standard Approach: Regulatory and industry best practices recommend establishing a single PK assay using one analytical standard (often the biosimilar itself) for the quantification of both the biosimilar and the reference product. This reduces inter-assay variability and supports blinded clinical studies.
• Validation Process: During assay validation, standard curves are constructed using the research-grade biosimilar in a relevant matrix (typically human serum) at multiple concentrations. Serum samples spiked with the reference and biosimilar are quantified against this curve to evaluate assay accuracy, precision, matrix effects, and analytical equivalence.
• Equivalence Assessment: Bioanalytical comparability is shown by measuring the biosimilar and reference products across the dynamic range of the assay and applying statistical analysis (such as 90% confidence intervals within an equivalence margin, e.g., [0.8, 1.25]).
• Lot-to-Lot Consistency: Commercial ELISA kits are validated lot-to-lot using such calibration standards and, where applicable, are cross-validated against international standards (e.g., NIBSC/WHO), with kit performance confirmed in spiked sample recovery and linearity tests.

This approach ensures the assay measures both biosimilar and reference Tisotumab accurately and interchangeably, providing reliable PK data critical for biosimilarity assessments in drug development.

The primary in vivo models used to administer research-grade anti-Tissue Factor (TF) antibodies for studying tumor growth inhibition and characterizing tumor-infiltrating lymphocytes (TILs) are:

• Syngeneic mouse models
• Humanized mouse models
• Orthotopic and subcutaneous xenograft models (using human tumors in immunodeficient mice)

Supporting Details:

1. Syngeneic Mouse Models:

• Definition: These models use mouse tumor cell lines implanted in immunocompetent mice of the same genetic background, preserving a functional murine immune system.
• Application: They allow for the analysis of how anti-TF antibodies influence both tumor growth and immune infiltration, including TILs, in the context of a complete immune response.
• TIL Characterization: Syngeneic models are highly suited for profiling TILs as they enable expansion, infiltration, and functional analysis within an intact murine immune environment.

2. Humanized Mouse Models:

• Definition: Immunodeficient mice are engrafted with functional human immune cells (e.g., PBMCs or CD34+ stem cells), enabling the study of human immune-tumor interactions.
• Application: These models are ideal for assessing the effects of anti-TF antibodies on tumor growth and for detailed investigation of human TIL phenotypes and function within the tumor microenvironment.
• Rationale: They are especially important for evaluating how anti-TF antibodies may engage human immune effector mechanisms mediated by TILs.

3. Xenograft Models (Human Tumor in Mice):

• Standard Xenograft: Human tumor cells are implanted into immunodeficient mice. Research-grade anti-TF antibodies (including antibody-drug conjugates) are commonly tested for tumor growth inhibition in these models.
• Orthotopic and Subcutaneous Sites: Models such as subcutaneous and orthotopic xenografts (where tumors are engrafted at organ-specific anatomical sites) are used to evaluate anti-tumor efficacy of anti-TF antibodies, but they often lack a competent immune system. Some studies focus on tumor growth inhibition as the primary endpoint, with limited capacity to characterize murine TILs unless the antibody cross-reacts with murine TF.
• Humanized Xenografts: Combining humanized mice with human tumor xenografts allows for both tumor growth assessment and full human TIL profiling.

Relevant Literature Examples:

• Anti-TF ADCs (antibody-drug conjugates) have been tested in both orthotopic and subcutaneous human tumor xenograft models for tumor growth inhibition, particularly in pancreatic cancer and triple-negative breast cancer.
• Syngeneic mice and humanized mouse models are cited as the main preclinical platforms for probing both tumor inhibition and TIL responses in immunotherapy research.

Summary Table: Primary Models for Anti-TF Antibody In Vivo Studies

In summary:
Syngeneic murine models and humanized mouse models are the primary platforms for both anti-tumor and TIL studies involving anti-TF antibodies in vivo. Xenograft models remain central to tumor inhibition studies, but characterization of TILs is best accomplished in models possessing either a functional murine or reconstituted human immune system.

Researchers use the Tisotumab biosimilar—an antibody that mimics the clinical antibody’s targeting of tissue factor (CD142)—in preclinical immune-oncology models to evaluate its effects either alone or in combination with other immune checkpoint inhibitors, such as anti-CTLA-4 or anti-LAG-3 biosimilars, to study synergistic anti-tumor effects.

Context and Application in Synergy Studies:

• Tisotumab biosimilar is designed for research use only, mimicking the mechanism of action of Tisotumab Vedotin by targeting tissue factor (TF) on cancer cells, making it suitable for high-throughput screening and in vivo/ex vivo mechanistic studies.
• In combination models, the Tisotumab biosimilar is administered together with checkpoint inhibitors (e.g., anti-CTLA-4 or anti-LAG-3 biosimilars) to simulate multi-pronged cancer immunotherapy regimens, reflecting clinical strategies aimed at overcoming resistance or suboptimal monotherapy responses.

How Synergy is Studied:

• Experimental Design: Tumor-bearing mice or human-derived organoid/xenograft models are treated with Tisotumab biosimilar alone, each checkpoint inhibitor alone, and the combinations. Tumor growth, immune infiltration, cytokine profiles, and survival are assessed for additive or synergistic anti-tumor effects.
• Rationale:
  • Checkpoint inhibitors (CTLA-4, LAG-3, PD-1/PD-L1) release different brakes on immune activation. For example, CTLA-4 blockers mainly act in lymph nodes to enhance T cell priming, while PD-1/PD-L1 inhibitors act at the tumor site to reinvigorate exhausted T cells.
  • Targeted therapies like Tisotumab-mediated TF blockade can directly kill tumor cells and potentially enhance tumor immunogenicity, increasing antigen release and presentation, thereby augmenting the efficacy of checkpoint inhibitors.
• Endpoints: Synergy is inferred when the combination achieves superior tumor control, enhanced T cell responses, or longer survival than either agent alone.

Additional Considerations:

• Mechanistic Assays: Researchers quantify T cell activation, tumor infiltration, apoptosis, cytokine release, and gene expression changes to dissect underlying mechanisms.
• Limitations: Tisotumab biosimilars are restricted to nonclinical (preclinical) use and do not contain the cytotoxic payload (e.g., MMAE) unless specifically engineered as conjugates. Findings from biosimilar-based immune-oncology models are foundational but require further validation before clinical translation.

In summary, using the Tisotumab biosimilar in combination with other checkpoint inhibitor biosimilars in complex models allows researchers to systematically characterize potential synergistic effects and mechanisms, guiding future combination immunotherapy development.

In immunogenicity testing, a Tisotumab biosimilar can be used as either a capture or detection reagent in a bridging ADA ELISA assay to monitor a patient's immune response—specifically, the development of anti-drug antibodies (ADAs) against the therapeutic drug.

Assay Principle and Use of Biosimilar:

• In a bridging ADA ELISA, both capture and detection reagents are typically the therapeutic drug itself (or a biosimilar version), labeled differently (e.g., one is biotinylated for plate capture, the other is enzyme-labeled for detection).
• When testing for ADAs, a patient serum sample is added; any ADA present will have two antigen-binding sites and can bind to both the capture and detection reagents, effectively "bridging" them into a detectable complex.
• A Tisotumab biosimilar is suitable for use in this assay because, as a biosimilar, it should be structurally and functionally comparable to the reference Tisotumab drug, thus ensuring that patient-derived ADAs (regardless of being generated in response to the originator or the biosimilar) can be effectively captured and detected.

Role as Capture or Detection Reagent:

• When used as a capture reagent, the biosimilar (e.g., biotin-labeled) is bound to a streptavidin-coated plate.
• For detection, the biosimilar may be conjugated to an enzyme (such as HRP) or a dye, allowing signal detection after the "bridge" is formed.
• This format enables high specificity for ADAs that are bivalent and recognize epitopes present on the biosimilar.

Advantages:

• The assay is highly sensitive for detecting antibodies that react with the drug, as both arms of the ADA must bind to the capture and detection reagents, reducing background signal from monovalent or non-specific binding.
• Using a biosimilar as the reagent ensures that the assay detects immune responses relevant to the therapeutic compound administered to the patient.

Considerations:

• It's crucial to validate that the biosimilar used in the assay mimics the immune epitopes of the originator exactly, ensuring that all clinically relevant ADAs are detected.
• Matrix effects from human serum or cross-reactivity with other serum components must be controlled with appropriate blocking and controls.
• Differences in glycosylation or other structural attributes between the biosimilar reagent and the therapeutic drug administered should be minimized to avoid false-negative or false-positive results.

In summary, in bridging ADA ELISA immunogenicity assays, a Tisotumab biosimilar is used (biotin- or enzyme-labeled) as both capture and/or detection reagent, allowing for the sensitive and specific detection of patient ADAs targeting Tisotumab. This is essential for monitoring potential immunogenicity and the impact on drug efficacy and safety during biosimilar development and clinical use.